Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Apyx Medical (APYX) EBIT (2016 - 2025)

Apyx Medical's EBIT history spans 15 years, with the latest figure at $11000.0 for Q4 2025.

  • For Q4 2025, EBIT rose 100.36% year-over-year to $11000.0; the TTM value through Dec 2025 reached -$6.4 million, up 65.79%, while the annual FY2025 figure was -$6.4 million, 65.79% up from the prior year.
  • EBIT reached $11000.0 in Q4 2025 per APYX's latest filing, up from -$832000.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $11000.0 in Q4 2025 to a low of -$6.6 million in Q1 2024.
  • Average EBIT over 5 years is -$4.0 million, with a median of -$4.3 million recorded in 2021.
  • Peak YoY movement for EBIT: plummeted 349.15% in 2024, then surged 100.36% in 2025.
  • A 5-year view of EBIT shows it stood at -$1.7 million in 2021, then tumbled by 250.65% to -$5.9 million in 2022, then grew by 2.65% to -$5.8 million in 2023, then soared by 47.23% to -$3.0 million in 2024, then soared by 100.36% to $11000.0 in 2025.
  • Per Business Quant, the three most recent readings for APYX's EBIT are $11000.0 (Q4 2025), -$832000.0 (Q3 2025), and -$2.6 million (Q2 2025).